Live search
TopFind is fetching the latest matches for your search.
We reviewed 6 live results for cosentyx and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Interleukin Inhibitor and Biologics.
Source: Novartis Malaysia
Description
Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe.
Best for
plaque psoriasis, psoriatic arthritis and interleukin inhibition
Rating
Source: Novartis Corporation (Malaysia) Sdn. Bhd.
Description
Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy.
Best for
plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home
Rating
Source: Novartis Pharmaceuticals Corporation
Description
A manufacturer-backed access program in the US that allows cash-paying patients to bypass traditional insurance hurdles to obtain secukinumab directly. This ensures continuous access for those without standard coverage.
Best for
cash-paying patients, uninsured individuals, US residents and manufacturer direct access
Rating
| Compare | Cosentyx | Cosentyx 150mg/ml | Cosentyx Direct-to-Patient Platform |
|---|---|---|---|
| Source | Novartis Malaysia | Novartis Corporation (Malaysia) Sdn. Bhd. | Novartis Pharmaceuticals Corporation |
| Description | Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe. | Secukinumab solution for injection available in a pre-filled pen or pre-filled syringe. This interleukin-17A (IL-17A) inhibitor is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults who are candidates for systemic therapy or phototherapy. | A manufacturer-backed access program in the US that allows cash-paying patients to bypass traditional insurance hurdles to obtain secukinumab directly. This ensures continuous access for those without standard coverage. |
| Best for | plaque psoriasis, psoriatic arthritis and interleukin inhibition | plaque psoriasis patients, psoriatic arthritis management, ankylosing spondylitis treatment and self-injection at home | cash-paying patients, uninsured individuals, US residents and manufacturer direct access |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Cosentyx from Novartis Malaysia."
I picked this because A targeted biologic therapy specifically effective for patients managing chronic plaque psoriasis and joint inflammation.